Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Plan S: A threat to quality of science?

Spedding M, Barrett J, Morgan ET, Vore M, Geraghty D, Kirkpatrick C, Cascorbi I.

Science. 2019 Feb 1;363(6426):462. doi: 10.1126/science.aaw1424. No abstract available.

PMID:
30705177
2.

Posttranslational regulation of CYP2J2 by nitric oxide.

Park JW, Lee CM, Cheng JS, Morgan ET.

Free Radic Biol Med. 2018 Jun;121:149-156. doi: 10.1016/j.freeradbiomed.2018.04.576. Epub 2018 Apr 30.

3.

Physiological Regulation of Drug Metabolism and Transport: Pregnancy, Microbiome, Inflammation, Infection, and Fasting.

Morgan ET, Dempsey JL, Mimche SM, Lamb TJ, Kulkarni S, Cui JY, Jeong H, Slitt AL.

Drug Metab Dispos. 2018 May;46(5):503-513. doi: 10.1124/dmd.117.079905. Epub 2018 Mar 7.

4.

Nitric oxide stimulates cellular degradation of human CYP51A1, the highly conserved lanosterol 14α-demethylase.

Park JW, Byrd A, Lee CM, Morgan ET.

Biochem J. 2017 Sep 14;474(19):3241-3252. doi: 10.1042/BCJ20170459.

5.

Nitric oxide-regulated proteolysis of human CYP2B6 via the ubiquitin-proteasome system.

Lee CM, Tripathi S, Morgan ET.

Free Radic Biol Med. 2017 Jul;108:478-486. doi: 10.1016/j.freeradbiomed.2017.04.015. Epub 2017 Apr 17.

6.

Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, lncRNAs, gut microbiota, and diseases: a meeting report of the 21st International Symposium on Microsomes and Drug Oxidations (MDO).

Yu AM, Ingelman-Sundberg M, Cherrington NJ, Aleksunes LM, Zanger UM, Xie W, Jeong H, Morgan ET, Turnbaugh PJ, Klaassen CD, Bhatt AP, Redinbo MR, Hao P, Waxman DJ, Wang L, Zhong XB.

Acta Pharm Sin B. 2017 Mar;7(2):241-248. doi: 10.1016/j.apsb.2016.12.006. Epub 2017 Feb 1.

7.

The receptor tyrosine kinase EphB2 promotes hepatic fibrosis in mice.

Mimche PN, Brady LM, Bray CF, Lee CM, Thapa M, King TP, Quicke K, McDermott CD, Mimche SM, Grakoui A, Morgan ET, Lamb TJ.

Hepatology. 2015 Sep;62(3):900-14. doi: 10.1002/hep.27792. Epub 2015 Apr 22.

8.

Cancer, inflammation, and therapy: effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents.

Harvey RD, Morgan ET.

Clin Pharmacol Ther. 2014 Oct;96(4):449-57. doi: 10.1038/clpt.2014.143. Epub 2014 Jul 2. Review.

PMID:
24987833
10.
11.

Selective and cytokine-dependent regulation of hepatic transporters and bile acid homeostasis during infectious colitis in mice.

Merrell MD, Nyagode BA, Clarke JD, Cherrington NJ, Morgan ET.

Drug Metab Dispos. 2014 Apr;42(4):596-602. doi: 10.1124/dmd.113.055525. Epub 2013 Dec 30.

12.

Hepatic cytochrome P450s, phase II enzymes and nuclear receptors are downregulated in a Th2 environment during Schistosoma mansoni infection.

Mimche SM, Nyagode BA, Merrell MD, Lee CM, Prasanphanich NS, Cummings RD, Morgan ET.

Drug Metab Dispos. 2014 Jan;42(1):134-40. doi: 10.1124/dmd.113.054957. Epub 2013 Oct 25.

13.

Nitric oxide and interleukin-1β stimulate the proteasome-independent degradation of the retinoic acid hydroxylase CYP2C22 in primary rat hepatocytes.

Lee CM, Lee BS, Arnold SL, Isoherranen N, Morgan ET.

J Pharmacol Exp Ther. 2014 Jan;348(1):141-52. doi: 10.1124/jpet.113.209841. Epub 2013 Oct 21.

14.

Selective modulation of hepatic cytochrome P450 and flavin monooxygenase 3 expression during citrobacter rodentium infection in severe combined immune-deficient mice.

Nyagode BA, Watkins WJ, Kinloch RD, Morgan ET.

Drug Metab Dispos. 2012 Oct;40(10):1894-9. doi: 10.1124/dmd.112.046557. Epub 2012 Jun 27.

15.

Nitric oxide-dependent CYP2B degradation is potentiated by a cytokine-regulated pathway and utilizes the immunoproteasome subunit LMP2.

Sun H, Lee CM, Tripathi S, Kim KB, Morgan ET.

Biochem J. 2012 Aug 1;445(3):377-82. doi: 10.1042/BJ20120820.

16.

The field of pharmacology and toxicology.

Morgan ET.

Drug Metab Dispos. 2012 Mar;40(3):413. doi: 10.1124/dmd.111.000009. No abstract available.

PMID:
22337621
17.

Selective role for tumor necrosis factor-α, but not interleukin-1 or Kupffer cells, in down-regulation of CYP3A11 and CYP3A25 in livers of mice infected with a noninvasive intestinal pathogen.

Kinloch RD, Lee CM, van Rooijen N, Morgan ET.

Biochem Pharmacol. 2011 Aug 1;82(3):312-21. doi: 10.1016/j.bcp.2011.04.016. Epub 2011 May 6.

18.

Metabolism and action of proteasome inhibitors in primary human hepatocytes.

Lee CM, Kumar V, Riley RI, Morgan ET.

Drug Metab Dispos. 2010 Dec;38(12):2166-72. doi: 10.1124/dmd.110.035501. Epub 2010 Sep 13.

19.

Modulation of hepatic cytochrome P450s by Citrobacter rodentium infection in interleukin-6- and interferon-{gamma}-null mice.

Nyagode BA, Lee CM, Morgan ET.

J Pharmacol Exp Ther. 2010 Nov;335(2):480-8. doi: 10.1124/jpet.110.171488. Epub 2010 Aug 18.

20.

Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics.

Morgan ET.

Clin Pharmacol Ther. 2009 Apr;85(4):434-8. doi: 10.1038/clpt.2008.302. Epub 2009 Feb 11. Review. No abstract available.

21.

Dual mechanisms of CYP3A protein regulation by proinflammatory cytokine stimulation in primary hepatocyte cultures.

Lee CM, Pohl J, Morgan ET.

Drug Metab Dispos. 2009 Apr;37(4):865-72. doi: 10.1124/dmd.108.026187. Epub 2009 Jan 26.

22.

Hepatic flavin-containing monooxygenase gene regulation in different mouse inflammation models.

Zhang J, Chaluvadi MR, Reddy R, Motika MS, Richardson TA, Cashman JR, Morgan ET.

Drug Metab Dispos. 2009 Mar;37(3):462-8. doi: 10.1124/dmd.108.025338. Epub 2008 Dec 16.

23.

TLR4-dependent and -independent regulation of hepatic cytochrome P450 in mice with chemically induced inflammatory bowel disease.

Chaluvadi MR, Nyagode BA, Kinloch RD, Morgan ET.

Biochem Pharmacol. 2009 Feb 1;77(3):464-71. doi: 10.1016/j.bcp.2008.10.029. Epub 2008 Nov 6.

24.

Regulation of hepatic cytochrome P450 expression in mice with intestinal or systemic infections of citrobacter rodentium.

Chaluvadi MR, Kinloch RD, Nyagode BA, Richardson TA, Raynor MJ, Sherman M, Antonovic L, Strobel HW, Dillehay DL, Morgan ET.

Drug Metab Dispos. 2009 Feb;37(2):366-74. doi: 10.1124/dmd.108.024240. Epub 2008 Oct 29.

25.

Metabolomics reveals that hepatic stearoyl-CoA desaturase 1 downregulation exacerbates inflammation and acute colitis.

Chen C, Shah YM, Morimura K, Krausz KW, Miyazaki M, Richardson TA, Morgan ET, Ntambi JM, Idle JR, Gonzalez FJ.

Cell Metab. 2008 Feb;7(2):135-47. doi: 10.1016/j.cmet.2007.12.003.

26.

Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer.

Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, Charles KA, Clarke SJ, Kacevska M, Liddle C, Richardson TA, Sharma R, Sinal CJ.

Drug Metab Dispos. 2008 Feb;36(2):205-16. doi: 10.1124/dmd.107.018747.

PMID:
18218849
27.

Roles of nitric oxide in inflammatory downregulation of human cytochromes P450.

Aitken AE, Lee CM, Morgan ET.

Free Radic Biol Med. 2008 Mar 15;44(6):1161-8. doi: 10.1016/j.freeradbiomed.2007.12.010. Epub 2007 Dec 23.

28.

Nitric oxide-dependent proteasomal degradation of cytochrome P450 2B proteins.

Lee CM, Kim BY, Li L, Morgan ET.

J Biol Chem. 2008 Jan 11;283(2):889-98. Epub 2007 Nov 9.

29.
30.

Catalytic characterization and cytokine mediated regulation of cytochrome P450 4Fs in rat hepatocytes.

Kalsotra A, Anakk S, Brommer CL, Kikuta Y, Morgan ET, Strobel HW.

Arch Biochem Biophys. 2007 May 1;461(1):104-12. Epub 2007 Mar 15.

31.

Inhibition of estrogen-induced mammary tumor formation in MMTV-aromatase transgenic mice by 4-chlorophenylacetate.

Sidell N, Kirma N, Morgan ET, Nair H, Tekmal RR.

Cancer Lett. 2007 Jun 28;251(2):302-10. Epub 2007 Jan 9.

32.

Regulation of drug-metabolizing enzymes and transporters in inflammation.

Aitken AE, Richardson TA, Morgan ET.

Annu Rev Pharmacol Toxicol. 2006;46:123-49. Review.

PMID:
16402901
33.

Hepatic and renal cytochrome p450 gene regulation during citrobacter rodentium infection in wild-type and toll-like receptor 4 mutant mice.

Richardson TA, Sherman M, Antonovic L, Kardar SS, Strobel HW, Kalman D, Morgan ET.

Drug Metab Dispos. 2006 Mar;34(3):354-60. Epub 2005 Dec 8.

34.

Expression of UDP-glucuronosyltransferase isoform mRNAs during inflammation and infection in mouse liver and kidney.

Richardson TA, Sherman M, Kalman D, Morgan ET.

Drug Metab Dispos. 2006 Mar;34(3):351-3. Epub 2005 Dec 8.

35.

Hepatic cytochrome P450 gene regulation during endotoxin-induced inflammation in nuclear receptor knockout mice.

Richardson TA, Morgan ET.

J Pharmacol Exp Ther. 2005 Aug;314(2):703-9. Epub 2005 Apr 28.

PMID:
15860574
36.

Effects of early maternal separation on ethanol intake, GABA receptors and metabolizing enzymes in adult rats.

Jaworski JN, Francis DD, Brommer CL, Morgan ET, Kuhar MJ.

Psychopharmacology (Berl). 2005 Aug;181(1):8-15. Epub 2005 Oct 15.

PMID:
15830234
37.

A role for one or more p450 enzymes in the response to sepsis.

Morgan ET.

Crit Care Med. 2005 Jan;33(1):268-9. No abstract available.

PMID:
15644701
38.

Transcriptional suppression of cytochrome P450 genes by endogenous and exogenous chemicals.

Riddick DS, Lee C, Bhathena A, Timsit YE, Cheng PY, Morgan ET, Prough RA, Ripp SL, Miller KK, Jahan A, Chiang JY.

Drug Metab Dispos. 2004 Apr;32(4):367-75. Review.

PMID:
15039287
39.

Inflammatory prompts produce isoform-specific changes in the expression of leukotriene B(4) omega-hydroxylases in rat liver and kidney.

Kalsotra A, Cui X, Antonovic L, Robida AM, Morgan ET, Strobel HW.

FEBS Lett. 2003 Dec 4;555(2):236-42.

40.

Rapid transcriptional suppression of rat cytochrome P450 genes by endotoxin treatment and its inhibition by curcumin.

Cheng PY, Wang M, Morgan ET.

J Pharmacol Exp Ther. 2003 Dec;307(3):1205-12. Epub 2003 Oct 13.

PMID:
14557382
41.

Expression of cytochromes P450 4F4 and 4F5 in infection and injury models of inflammation.

Cui X, Kalsotra A, Robida AM, Matzilevich D, Moore AN, Boehme CL, Morgan ET, Dash PK, Strobel HW.

Biochim Biophys Acta. 2003 Feb 17;1619(3):325-31.

PMID:
12573492
42.

Mechanisms of cytochrome P450 regulation by inflammatory mediators.

Morgan ET, Li-Masters T, Cheng PY.

Toxicology. 2002 Dec 27;181-182:207-10. Review.

PMID:
12505312
44.

Cytochromes P450 and flavin monooxygenases--targets and sources of nitric oxide.

Morgan ET, Ullrich V, Daiber A, Schmidt P, Takaya N, Shoun H, McGiff JC, Oyekan A, Hanke CJ, Campbell WB, Park CS, Kang JS, Yi HG, Cha YN, Mansuy D, Boucher JL.

Drug Metab Dispos. 2001 Nov;29(11):1366-76.

PMID:
11602511
45.

Hepatic cytochrome P450 regulation in disease states.

Cheng PY, Morgan ET.

Curr Drug Metab. 2001 Jun;2(2):165-83. Review.

PMID:
11469724
46.

Role of nitric oxide in down-regulation of CYP2B1 protein, but not RNA, in primary cultures of rat hepatocytes.

Ferrari L, Peng N, Halpert JR, Morgan ET.

Mol Pharmacol. 2001 Jul;60(1):209-16.

PMID:
11408616
47.

Regulation of hepatic cytochrome P450 2C11 via cAMP: implications for down-regulation in diabetes, fasting, and inflammation.

Iber H, Li-Masters T, Chen Q, Yu S, Morgan ET.

J Pharmacol Exp Ther. 2001 Apr;297(1):174-80.

PMID:
11259542
48.

Effects of bacterial lipopolysaccharide on phenobarbital-induced CYP2B expression in mice.

Li-Masters T, Morgan ET.

Drug Metab Dispos. 2001 Mar;29(3):252-7.

PMID:
11181491
49.

Regulation of cytochrome p450 by inflammatory mediators: why and how?

Morgan ET.

Drug Metab Dispos. 2001 Mar;29(3):207-12. Review. Erratum in: Drug Metab Dispos 2001 Jun;29(6):932.

PMID:
11181485
50.

Supplemental Content

Loading ...
Support Center